532039
Zenotech Lab. financials
- Market cap
- ₹275 Cr
- Sector
- Healthcare
What Zenotech Lab. does
Zenotech Laboratories Limited is a pharmaceutical company based in Hyderabad, Telangana, engaged in the manufacture of sterile formulations. It operates from a single manufacturing facility, which also serves as its registered office, at Turkapally Village, Shamirpet Mandal. The company manufactures products offered by Sun Pharmaceutical Industries Limited, its holding company/promoter, under a Loan Licensing arrangement, and its current operations mainly depend on Sun Pharma.
Segments
- Sterile formulations manufacturing
- Manufacturing facilities
- 1 (Turkapally Village, Shamirpet Mandal, Hyderabad, Telangana)
- Permanent employees
- 228 (FY25)
- Manufacturing arrangement
- Loan License manufacturer for Sun Pharmaceutical Industries Limited
- Product focus
- Sterile formulations
Quarterly results
Q1 FY27: revenue up 10.2%, net profit down 146.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 11 | 12 | 10 | 11 +15% | 13 +14% | 10 −18% | 11 +10% |
| EBITDA | 2 | 4 | 4 | 2 | 2 −5% | 4 +10% | 0 −96% | 1 −65% |
| Net profit | 1 | 2 | 1 | 1 | -1 −162% | 2 +14% | -3 −356% | -0 −146% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −19.7% 1Y
1Y: ₹55.4 on 10 Sept 2025 → ₹44.5. High ₹55.62 (12 Sept 2025), low ₹34.29 (30 Mar 2026).
Financials, as filed
Revenue grew 0.9% a year over 3 years, FY23 to FY26. Operating margin narrowed to 21.1%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹42 Cr | ₹41 Cr | ₹43 Cr | ₹44 Cr |
| Operating profit | ₹21 Cr | ₹17 Cr | ₹14 Cr | ₹9 Cr |
| Operating margin | 48.8% | 42.2% | 32.9% | 21.1% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr |
| Net profit | ₹12 Cr | ₹8 Cr | ₹6 Cr | ₹-1 Cr |
| Net margin | 27.3% | 20.3% | 12.9% | -2.5% |
| Cash from operations | ₹21 Cr | ₹12 Cr | ₹9 Cr | ₹10 Cr |
| Free cash flow | ₹14 Cr | ₹8 Cr | ₹6 Cr | ₹2 Cr |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹61 Cr | ₹61 Cr | ₹61 Cr | ₹61 Cr | ₹61 Cr | ₹61 Cr |
| Reserves | ₹-13 Cr | ₹10 Cr | ₹21 Cr | ₹30 Cr | ₹35 Cr | ₹34 Cr |
| Borrowings | ₹21 Cr | ₹6 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other liabilities | ₹17 Cr | ₹17 Cr | ₹19 Cr | ₹16 Cr | ₹15 Cr | ₹16 Cr |
| Total liabilities | ₹86 Cr | ₹94 Cr | ₹101 Cr | ₹106 Cr | ₹111 Cr | ₹111 Cr |
| Fixed assets | ₹74 Cr | ₹71 Cr | ₹65 Cr | ₹66 Cr | ₹60 Cr | ₹62 Cr |
| Capital work in progress | ₹2 Cr | ₹0 Cr | ₹5 Cr | ₹2 Cr | ₹5 Cr | ₹4 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹9 Cr | ₹23 Cr | ₹31 Cr | ₹39 Cr | ₹46 Cr | ₹45 Cr |
| Total assets | ₹86 Cr | ₹94 Cr | ₹101 Cr | ₹106 Cr | ₹111 Cr | ₹111 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 5% to 10,161.
- Promoters
- 68.8%
- DIIs
- 0.0%
- Government
- 1.0%
- Public
- 30.2%
Since Jun 2025
- Promoters 0.00 pp
- DIIs 0.00 pp
- Government 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Dec '23: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Mar '24: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Jun '24: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Sep '24: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Dec '24: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Mar '25: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Jun '25: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Sep '25: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Dec '25: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Mar '26: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.Jun '26: Promoters 68.8%, DIIs 0.0%, Government 1.0%, Public 30.2%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Padmasree Chigurupati +0.26 pp 5.52% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Zenotech Lab. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 68.84% | unchanged |
| Padmasree Chigurupati | 5.52% | +0.26 pp |
| Pat Financial Consultants Private Limited | 3.98% | unchanged |
| Dr. Jayaram Chigurupati | 3.33% | −0.26 pp |
| Minal Bharat Patel | 1.72% | unchanged |
| Zenotech Llc | 1.14% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Zenotech Lab.
Guides on how to read this kind of business and the numbers that matter.